Abstract
Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH
| Original language | English |
|---|---|
| Pages (from-to) | 543-548 |
| Number of pages | 5 |
| Journal | European Journal of Endocrinology |
| Volume | 160 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Dive into the research topics of 'Pituitary-independent effect of octreotide on IGF1 generation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver